TY - JOUR
T1 - A risk-based approach to acute coronary syndromes, Part 2
T2 - NSTE-MI and UA: How to maximize the benefit of drugs and procedures, before and after discharge
AU - Hudson, M. P.
AU - Peterson, E. D.
PY - 2000
Y1 - 2000
N2 - Patients with acute coronary syndromes without ST-segment elevation are at variable risk for death and myocardial infarction or reinfarction, depending on clinical, ECG, and laboratory findings. Reassess risk throughout the hospital course. ST-segment depression or elevated cardiac enzyme levels indicate high risk; patients without those findings but with known or probable coronary artery disease are at moderate risk. Treat moderate- and high-risk patients with aspirin and heparin; also administer a glycoprotein IIb/IIIa inhibitor to high-risk patients. For patients with recurrent ischemia, heart failure, or arrhythmias during hospitalization, strongly consider early angiography and revascularization. At discharge, prescribe aspirin, β-blocker, and angiotensin-converting enzyme inhibitor therapy; aggressive lipid lowering with 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitors is recommended as well.
AB - Patients with acute coronary syndromes without ST-segment elevation are at variable risk for death and myocardial infarction or reinfarction, depending on clinical, ECG, and laboratory findings. Reassess risk throughout the hospital course. ST-segment depression or elevated cardiac enzyme levels indicate high risk; patients without those findings but with known or probable coronary artery disease are at moderate risk. Treat moderate- and high-risk patients with aspirin and heparin; also administer a glycoprotein IIb/IIIa inhibitor to high-risk patients. For patients with recurrent ischemia, heart failure, or arrhythmias during hospitalization, strongly consider early angiography and revascularization. At discharge, prescribe aspirin, β-blocker, and angiotensin-converting enzyme inhibitor therapy; aggressive lipid lowering with 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitors is recommended as well.
UR - http://www.scopus.com/inward/record.url?scp=0033975708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033975708&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0033975708
SN - 1040-0257
VL - 15
SP - 81
EP - 86
JO - Journal of Critical Illness
JF - Journal of Critical Illness
IS - 2
ER -